IL1B and atherosclerosis: Although the incidence of atherosclerosis-related cardiovascular events has been clinically reduced by the use of anti-IL-1β therapy, as shown in several large-scale population cohort trials (Table 1), the clinical effect of IL-1β inhibition on atherosclerotic vascular calcification remains unclear.